Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

16 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IGR_BREAST_EXON_AGILENT_STUDY_FA

ABSTRACT: We profiled breast cancer samples with exon arrays (244K Agilent Human exon) in order to identify exons associated with higher risk of relapse. This set contain 178 single dual color of samples (biopsies) versus normal breast reference (Normal breast Clontech) , 5 dye-swap (10 hybridizations) and 5 self self for controls.

ORGANISM(S): Homo sapiens

DISEASE(S): breast adenocarcinoma

SUBMITTER: Philippe DESSEN

PROVIDER: E-MTAB-1389 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics.

Molina Angie A Velot Lauriane L Ghouinem Lydia L Abdelkarim Mohamed M Bouchet Benjamin Pierre BP Luissint Anny-Claude AC Bouhlel Imène I Morel Marina M Sapharikas Elène E Di Tommaso Anne A Honoré Stéphane S Braguer Diane D Gruel Nadège N Vincent-Salomon Anne A Delattre Olivier O Sigal-Zafrani Brigitte B André Fabrice F Terris Benoit B Akhmanova Anna A Di Benedetto Mélanie M Nahmias Clara C Rodrigues-Ferreira Sylvie S

Cancer research 20130208 9

Metastasis, a fatal complication of breast cancer, does not fully benefit from available therapies. In this study, we investigated whether ATIP3, the major product of 8p22 MTUS1 gene, may be a novel biomarker and therapeutic target for metastatic breast tumors. We show that ATIP3 is a prognostic marker for overall survival among patients with breast cancer. Notably, among metastatic tumors, low ATIP3 levels associate with decreased survival of the patients. By using a well-defined experimental m ...[more]

PMID: 23396587

Similar Datasets

Transcription profiling by array on 123 paired tumor and non-tumor tissue samples from patients with non-small cell lung carcinoma to gain a systems biology insight into the current clinical classification

Project description:Non-small cell lung cancer (NSCLC), a leading cause of cancer deaths, represents a heterogeneous group of neoplasms, mostly comprising squamous cell carcinoma (SCC), adenocarcinoma (AC) and large-cell carcinoma (LCC). The aim of this study was to gain a systems biology insight into the current clinical classification. Patients and Methods: Comparative genomic hybridization followed by mutational analysis, gene expression and miRNA microarray profiling were performed on 123 paired tumor and non-tumor tissue samples from patients with NSCLC. Using integrated systems biology approaches, we sought to find out if combining data types from different levels of biology would improve clinical assessment of NSCLC. Results: At both DNA, RNA and miRNA levels we could identify molecular markers that discriminated significantly between the various clinicopathological entities of NSCLC. Conclusions: We report proofs of distinct molecular profiles that contribute to distinguishing NSCLC tumor subtypes even in small biopsies. The Gene expression experiments have been made in dual color and dye_swap with Agilent human Human Genome Exon 244K arrays (custom design 14891, from commercial 4x44K (design 014850 plus 195000 oligo - 1 per exon- defined with RefSeq hg18 and 1840 probes from viral transcripts). Note date of surgery is the date of the sample was frozen.

2013-12-11 | E-MTAB-1132 | biostudies-arrayexpress

Transcription profiling by array of breast cancer distant metastasis based on outcome over time and identification of pathway activities of late relapse

Project description:Previous reports have described the use of microarrays to assess the molecular classification of human breast cancers and defined new subgroups based on gene expression that are relevant to patient management through their ability to predict metastatic relapse and survival relapse. However, different mechanisms may be associated with the development of early and late distant metastases. With the hypothesis that tumors may lead to early or distant metastases based on their intrinsic biological initial features. We aimed at defining molecular profiles for several subgroups of patients based on their outcome over time. Breast primary tumors were selected from retrospective series of patients with frozen material available. These series include patients of all ages, LN- and LN+; Estrogen or Progesteron-receptor positive, Her2-negative, no adjuvant treatment, with a follow-up of more than 10 years (y) for the control group or distant metastatic relapse as first event (DM) for the study group. Patients tumors were classified in 3 groups: no relapse at 10y (M0), DM before 5 y (M0-5), DM between 5 and 15 y (M5-15).Gene expression analysis of breast tumor samples was performed using custom-made Agilent 4x44K high-density microarrays and hybridized against the Mammaprint reference pool (MRP). MRP=MammaReference Pool (The reference sample consisted of pooled and amplified RNA of 105 primary breast tumors, see Glas AM, BMC Genomics, 2006). The design of this study consists to 20 hybridizations in dual color with Agilent Human Genome 4x44K (design 014850) of breast tumors with a MRP reference with an addition as controls of 2 dye swaps and two self-self of the MRP and HMG (Human normal mammary Gland , Clontech).

2013-08-01 | E-MTAB-949 | biostudies-arrayexpress

Transcription profiling of non-small cell lung carcinoma cell line H1975 treated with cisplatin or BMS-69014 a novel panHER/VEGFR inhibitor

Project description:Non-small cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor (EGFR) responds to EGFR tyrosine kinase inhibitors such as erlotinib. However, secondary somatic EGFR mutations (e.g. T790M) confer resistance to erlotinib. BMS-690514, a novel panHER/VEGFR inhibitor described here, exerted antiproliferative and pro-apoptotic effects on NSCLC cell lines, with prominent efficacy on H1975 cells expressing the T790M mutation. In this model, BMS-690514 induced a G1 cell cycle arrest, as well as ultrastructural hallmarks of apoptosis, mitochondrial release of cytochrome c, and activation of caspases involved in the intrinsic (e.g. caspase -2, -3, -7 and -9), but not in the extrinsic (e.g. caspase-8) pathway. Caspase inhibition conferred partial protection against BMS-690514 cytotoxicity, pointing to the involvement of both caspase-dependent and -independent effector mechanisms. Transcriptome analyses revealed the upregulation of pro-apoptotic (e.g. Bim, Puma) and cell cycle inhibitory (e.g. p27Kip1, p57Kip2) factors, as well as the downregulation of anti-apoptotic (e.g. Mcl1), heat shock (e.g. HSP40, HSP70, HSP90) and cell cycle promoting (e.g. cyclins B1, D1 and D3, CDK1, MCM family proteins, PCNA) proteins. BMS-690514-induced death of H1975 cells was modified in a unique fashion by a panel of siRNAs targeting apoptosis modulators. Downregulation of components of the NF-kappaB survival pathway (e.g. p65, Nemo/IKK, TAB2) sensitized cells to BMS-690514, whereas knockdown of pro-apoptotic factors (e.g. Puma, Bax, Bak, caspase-2, etc) and DNA damage-related proteins (e.g. ERCC1, hTERT) exerted cytoprotective effects. BMS-690514 is a new pan-HER/VEGFR inhibitor that may become an alternative to erlotinib for the treatment of NSCLC.

2007-07-24 | E-TABM-239 | biostudies-arrayexpress

Gene profiling of human primary fibroblasts treated with IDH2 inhibitor

Project description:Gene profiling of human primary fibroblasts treated with IDH2 inhibitor or vehicle (DMSO), for 3 or 6 days

2023-03-22 | E-MTAB-12637 | biostudies-arrayexpress

Transcription profiling of human TRAIL-resistant metastatic vs primary TRAIL-sensitive melanoma cells

Project description:T1 and G1 are the two melanoma cell lines, established from primary tumor (T1) and lymph node metastases (G1) of a 77 years old male patient. While G1 cells were resistant to TRAIL (TNF-related apoptosis-inducing ligand) mediated cell death, T1 cells exhibited a high dose- and time-dependent sensitivity to TRAIL. Cells were treated with or without of two doses (0.2 and 1ug/ml) of TRAIL for 24 h. Gene expression of each sample vs pool was measured. TRAIL-resistant metastatic G1 vs primary TRAIL-sensitive T1 was compared.

2006-01-01 | E-MEXP-247 | biostudies-arrayexpress

Transcription profiling of human xenografted nasopharyngeal carcinoma tumor cell lines and an untransformed diploid fibroblast cell line

Project description:The aim of this experiment was to investigate the gene expression profile of two xenografted nasopharyngeal carcinoma tumors - C15 and C17 which are international reference tools for biological investigations of this type of disease. C15 and C17 transcriptome was profiled by comparison with human untransformed diploid fibroblasts, MRC5. These fibroblasts are very sensitive to contact inhibition and were collected after 3 days of confluence, therefore in a quiescent state. We acknowledge that malignant nasopharyngeal carcinoma cells and MRC5 cells do not belong to the same lineage (epithelial cells versus fibroblasts). However this combination was expected to highlight genes involved in proliferation of NPC cells. Competitive hybridisation of cDNA for each pair C15 and MRC5, C17 and MRC5 was performed on Agilent microarrays containing 22 000 60mer oligonucleotides related to 16 000 human transcripts. The analysis was focused mainly on genes overexpressed in both C15 and C17 by comparison with MRC5

2007-12-01 | E-TABM-382 | biostudies-arrayexpress

Transcription profiling of 9 pairs of human metastasis/primary melanoma (each from the same patient)

Project description:Study by dye-swap of 9 pairs of metastasis/primary melanoma (each from the same patient)

2007-04-01 | E-TABM-4 | biostudies-arrayexpress

Transcription profiling of cohort of human cutaneous primary melanomas associated with a distant metastasis free survival

Project description:Identification of genomic characteristics in a cohorte of human cutaneous primary melanoma associated with a distant metastasis free survival.

2007-04-01 | E-TABM-1 | biostudies-arrayexpress

Comparative genomic hybridization of 23 human nevi with a pool of primary cutaneous melanoma

Project description:Genomic profiles comparing 23 nevi with a pool of primary cutaneous melanoma

2009-04-16 | E-TABM-3 | biostudies-arrayexpress

Transcription profiling of human cutaneous primary melanomas in an independent population of 17 patients

Project description:Validation of genomics characteristics of human cutaneous primary melanoma in an independnat population of 17 patients.

2007-04-01 | E-TABM-2 | biostudies-arrayexpress